Biodesix, Inc. Common Stock (BDSX) is a publicly traded Healthcare sector company. As of November 5, 2026, BDSX trades at $15.88 with a market cap of $226.74M and a P/E ratio of -5.48. BDSX moved -8.05% today. Year to date, BDSX is +220.31%; over the trailing twelve months it is +132.03%. Its 52-week range spans $3.44 to $31.97. Analyst consensus is strong buy with an average price target of $39.00. Rallies surfaces BDSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biodesix Q3 revenue rises 10% to $24.04 million; 2026 guidance is $101 million–$103 million: Biodesix reported third-quarter revenue of $24.04 million, up 10% year over year but below the $27.49 million analyst estimate. Net loss narrowed 8% to $8.03 million, and the company revised 2026 revenue guidance to $101 million–$103 million.
| Metric | Value |
|---|---|
| Price | $15.88 |
| Market Cap | $226.74M |
| P/E Ratio | -5.48 |
| EPS | $-4.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.97 |
| 52-Week Low | $3.44 |
| Volume | 157.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $88.50M |
| Net Income | $-35.27M |
| Gross Margin | 0.00% |
7 analysts cover BDSX: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.00.